Mercury Pharmaceuticals

We are de-risking biomedical innovations, while turning biomedical knowledge into social and economic value.

Stay Informed!

NEWS2 score may improve antibiotic decisions in suspected sepsis

6

Aug 2026

NEWS2 score may improve antibiotic decisions in suspected sepsis

A study of nearly 100,000 adults treated for suspected infection suggests that the National Early Warning Score (NEWS2), a score based on routinely collected vital signs that is widely used to identify patients at risk of clinical deterioration, may help clinicians identify which patients are most likely to benefit from immediate antibiotic treatment and which may safely undergo further evaluation before receiving antibiotics.

Older men’s sexual priorities extend well beyond erectile function

6

Aug 2026

Older men’s sexual priorities extend well beyond erectile function

A web-based survey of 6,000 Japanese men aged 50 or older found that sexual arousal was the function they most wanted to preserve, while erection became more highly valued as erectile function worsened. Erection showed the earliest age-related decline pattern, whereas ejaculation was the function most often reported as lost in older age.

MERCURY trials

Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more

Cancer

Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more

Neuroscience

Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more

Mercury Pharmaceuticals

Why Us?

Strong experience in academic research and technology transfer makes us understand your goals and motivations as a technology originator.
Our experience in drug development from discovery to clinical and commercial stages makes us an insider player within the biopharmaceutical industry.
Smart approach to project management that helps speed up development stages and decision making.
Availability of own investment up to 2m€ per project allows us to reach the next value milestone.